Kaku K, Kadowaki T, Seino Y, et al. - Researchers present the results of two clinical trials to unveil the efficacy, safety, as well as the tolerability of ipragliflozin 50 mg once daily (q.d.) added to sitagliptin 50 mg q.d. monotherapy among Japanese patients suffering from type 2 diabetes (T2D). Participants in both trials had HbA1c 7.0-10.0% on sitagliptin 50 mg q.d. 2 weeks before addition of ipragliflozin or placebo. In one trial (843), patients were randomly assigned 1:1 to addition of blinded ipragliflozin 50 mg q.d. (n = 73) or placebo (n = 70) for 24 weeks. In the other trial (849), open-label ipragliflozin 50 mg q.d. was added for 52 weeks (n = 77). Findings showed that significant improvement in glycemic control as well as generally good tolerability were offered by ipragliflozin 50 mg q.d. added on to sitagliptin 50 mg q.d. monotherapy in Japanese patients with T2D.